Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial
고위험 COVID-19 환자의 항바이러스 및 면역조절 인터페론-베타: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] acting
Acute respiratory failure
acutely ill patient
acutely ill patients
addition
Admission
age
allergy
anamnesis
antiretroviral
Antiviral
Antiviral treatment
approach
ARMS
assigned
Asthma
Autoimmune disease
AVPU
being
binding antibody
Blinding
block
blocks
blood pressure
blood sample
bridge
calculated
Care
cartridge
Chemotherapy
chronic kidney diseases
clinical assessment
Clinical Center
clinical centers
Clinical deterioration
clinical monitoring
Clinical sign
conducted
Control
control arm
control group
control patients
Controlled
COVID-19
COVID-19 symptoms
crackles
creatinine
criteria
cytokine
Darmstadt
Day
death
Dementia
determined by
diagnosed
disease
Disease progression
dissemination
dose
Efficacy
EGFR
Elderly patient
element
eligible
Eligible patients
Endpoint
enrolled
enrolment
EudraCT
evaluate
Evidence
evidence of
exclusion criteria
expected
experimental arm
female
following
form
Gender
Germany
Health
heart rate
High-dose
HIV infection
Hospitalized
hospitalized patients
hypersensitivity
ICU
identification number
IFN
IFN-β
IFNβ
immunomodulation
immunomodulatory
immunomodulatory property
immunosuppressive
Impaired
impairing
inclusion criteria
increase in
Infectious disease
Infectious diseases
Informed consent
injected
injection
intensive care unit
interferon
Interferon-beta
investigator
involved
kidney
laboratory-confirmed SARS-CoV-2 infection
Lazzaro Spallanzani
less
level of care
Life expectancy
low-dose
male
management
mechanical ventilation
mild COVID-19 symptom
mild COVID-19 symptoms
multiple sclerosis
Nasopharyngeal swab
nasopharyngeal swabs
National Early Warning Score
NEWS2
non-hospitalized patients
normal range
number
objective
Older
open
Open-label
outcome
oxygen
oxygen saturation
participant
Patient
patient identification
patients
patients treated
PCR
performed
phase
physical
physician
Presence
primary endpoint
proportion
protocol
provide
Psychological
pulse
rales
randomised
randomised controlled trial
randomization
randomization system
Randomized
Randomly
receive
recruitment
reducing
reduction in
Regional
registration date
relapsing
renal function
Respiratory failure
respiratory rate
responsible
resulting
risk
Rome
room air
RT-PCR
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 RT-PCR
score
Secondary objective
Secondary objectives
selected
sequence
severe COVID-19
severe depression
severe disease
specimen
SpO2
Standard of care
status
stratified
Stratified randomization
Study protocol
subcutaneously
subject
supervision
supplemental oxygen
supplementary material
symptomatic
temperature
Toxicity
treat
Treatment
treatment arm
treatment group
Trial
Trial registration
unique
unit
venous
venous blood
Version
vital signs
website
Withdrawal
worsening
written Informed Consent
[DOI] 10.1186/s13063-021-05367-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05367-6 PMC 바로가기 [Article Type] Letter